Next Article in Journal
Advances and Challenges in Targeting TGF-β Isoforms for Therapeutic Intervention of Cancer: A Mechanism-Based Perspective
Previous Article in Journal
The Role of α-Enolase on the Production of Interleukin (IL)-32 in Con A-Mediated Inflammation and Rheumatoid Arthritis (RA)
Previous Article in Special Issue
1,2,4-Triazole-Tethered Indolinones as New Cancer-Fighting Small Molecules Targeting VEGFR-2: Synthesis, Biological Evaluations and Molecular Docking
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Pharmaceuticals
Volume 17
Issue 4
10.3390/ph17040532
pharmaceuticals-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Synergistic Biomedical Potential and Molecular Docking Analyses of Coumarin–Triazole Hybrids as Tyrosinase Inhibitors: Design, Synthesis, In Vitro Profiling, and In Silico Studies

by
Rukhsana Kausar
1,
Ameer Fawad Zahoor
1,*,
Hina Tabassum
2,
Shagufta Kamal
3 and
Mashooq Ahmad Bhat
4,*
1
Department of Chemistry, Government College University Faisalabad, Faisalabad 38000, Pakistan
2
Department of Pharmacology, London Metropolitan University, 166-220 Holloway Road, London N7 8DB, UK
3
Department of Biochemistry, Government College University Faisalabad, Faisalabad 38000, Pakistan
4
Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia
*
Authors to whom correspondence should be addressed.
Pharmaceuticals 2024, 17(4), 532; https://doi.org/10.3390/ph17040532
Submission received: 24 March 2024 / Revised: 9 April 2024 / Accepted: 15 April 2024 / Published: 20 April 2024
(This article belongs to the Special Issue The Role of Molecular Docking in the Design of Targeted Therapeutic Entities and Nanomaterials)
Browse Figures
Versions Notes

Abstract

:
The tyrosinase enzyme has a vital role in the browning of vegetables and fruits and the biosynthesis of melanin. In this work, we synthesized a diverse library of coumarin–triazole hybrids, and these compounds were characterized by using suitable analytical techniques. Our research work extends beyond the synthetic effort to explore the therapeutic potential of these compounds. We put the synthesized compounds through meticulous in vitro screening against the tyrosinase enzyme, and these coumarin derivatives evinced good IC50 values in the range of 0.339 ± 0.25 µM to 14.06 ± 0.92 µM. In the library of synthesized compounds, six compounds were found to be more potent than standard ascorbic acid (IC50 = 11.5 ± 1.00), and among them, 17e and 17f, being the most active, exhibited remarkable anti-tyrosinase potential, with IC50 values of 0.339 ± 0.25 μM and 3.148 ± 0.23 μM, respectively. Furthermore, an in silico modeling study was carried out to determine the key interactions of these compounds with the tyrosinase protein (PDB ID: 2Y9X) and thus to authenticate our experimental findings. The quantitative SAR studies exhibited a good correlation between the synthesized derivatives of coumarin and their anti-tyrosinase activity. The docking studies verified the experimental results, and ligand 17e showed good interaction with the core residues of tyrosinase. This study not only expands the field of coumarin–triazole hybrid synthesis but also provides valuable insights for the development of novel tyrosinase inhibitors.

1. Introduction

Tyrosine, a precursor for the biosynthesis of catecholamines, including tyramine, L-DOPA, and dopamine, is oxidized to dopaquinone in mammalian melanogenesis by the copper-containing enzyme tyrosinase [1,2,3]. Melanogenesis in skin is a requisite for protection against UV radiation, which causes skin cancer, while an excessive amount of melanin can cause diseases like cancer, solar lentigo, ephelis, age spots, melanoderma, and malignant melanoma [4]. In addition, tyrosinase catalyzes the synthesis of neuromelanin in the brain and other polyphenolic compounds in the hair and skin [5]. Moreover, tyrosine is responsible for the process aimed at perpetuating the flavor, nutritional value, appearance, and texture of many fruits. Both elevated and low tyrosine levels in biological fluids are associated with many metabolic disorders. The browning of fruits and fungi after the harvest of crops such as mushrooms and that of beverages are also due to an abnormal level of tyrosine in plants [6]. Women are vulnerable to dermatological disorders such as freckles, senile lentigo, pigmented acne scars, and melasma, and these hyper-pigmentation conditions are directly associated with hyper-accumulation of melanin [7].
Compounds with inhibition activity for tyrosinase have been used for the treatment of hyper-pigmentation of the skin and the enzymatic browning of fruits [8]. Neurodegenerative diseases including Parkinson’s are also related to a high level of tyrosine in body fluids [9]. It has been found that tyrosinase is linked with different biochemical processes taking place in insects, such as defensive encapsulation and the sclerotization of cuticles [10]. Taking into consideration the importance of tyrosinase inhibitors, medicinal chemists are engaged in an abiding search for novel, effective, and safe tyrosinase inhibitors. The synthesis of an efficient and effective arsenal of compounds (anti-tyrosinase) is of eminent concern in the agricultural, medical, and cosmetic industries [11]. Many natural compounds have been found as potent tyrosinase inhibitors; for example, flavonoid derivatives are reported as the strongest inhibitors of tyrosinase [12]. Kojic acid (1), tropolone (2), ascorbic acid (4), and 1-phenylurea (3), depicted in Figure 1, are naturally occurring compounds with potent tyrosinase inhibition activity [13]. However, these natural drugs still have unpleasant side-effects, such as dermatitis, cutaneous melanoma, and cytotoxicity. These problems lead us to design more active and safer tyrosinase inhibitors [14]. Heterocycles such as coumarins [15], quinoxalines [16], oxadiazoles [17,18,19], acefylline [20], triazoles [21], lamivudines [22], thiadiazoles [23,24], quinoxaline-sulfonamides [25], ciprofloxacin-oxadiazoles [26], etc., show a variety of biological activities against different diseases.
Coumarin derivatives are captivating compounds due to the presence of coumarin (as a structural motif) in many natural drugs with interesting photophysical properties and biological applications [27,28]. In addition to having anti-oxidant and anti-microbial activities [29], coumarins are considered to represent an important class of organic compounds amenable to act as anti-cancer agents [30]. Coumarins are also very familiar as anti-HIV [31], anti-coagulant [32], and immunosuppressive drugs [33]. Some coumarin-based drugs are depicted in Figure 2. In addition to their pharmacological uses, molecules with a coumarin core have also been found to be used as luminescent probes, food additives, and dyes [34]. Matos et al. synthesized dihydroxy thiophene substituted coumarin as a potent anti-tyrosinase agent with an IC50 = 0.19 µM [35]. As a consequence of coumarin’s applications in various fields, modifications of this scaffold have been profoundly researched. A number of coumarin scaffolds (5–9) commonly employed as drugs are presented in Figure 2.
Triazole analogs are considered a large array of medicinally valuable compounds [36] owing to their anti-tubercular, anti-microbial, anti-viral, and anti-cancer activities [37,38]. Particularly, many compounds with a 1,2,4-triazole moiety are found to be potent inhibitors of tyrosinase [39,40,41,42,43,44]. Coumarins and triazoles are structural motifs that show tremendous potential biological activity due to their high therapeutic indexes [45,46]. Since both triazoles and lactones are biologically active pharmacophores, novel molecules with these bioactive moieties have been found to be more effective drugs than the parent compounds with a single moiety. For instance, the triazole–coumarin hybrids exhibit potential nonpeptidic [47], protease transglutaminase [48], glycogen phosphorylase, and glucose-6-phosphatase [49] inhibition activities.
Some of the coumarin derivatives also exhibit inhibition activity against the tyrosinase enzyme [50,51,52]. According to Li and coworkers (2023), 2-(1-(coumarin-3-yl)ethylidene)hydrazine carbothio-amide (10) (Figure 3) is a potent tyrosinase inhibitor with an IC50 of 3.04 µM [53].
So far, the best possible drug for tyrosinase inhibition is yet to be synthesized, and in this regard, a meticulous search for an innovative tyrosinase inhibitor is still required. Molecular hybridization, which has been considered an important strategy to design novel drugs, combines two or more biologically active moieties to synthesize a new pharmacological hybrid molecule [54].
Molecular hybridization is the main strategy to enhance the biological potential of heterocycles and can possibly overcome the challenge of drug resistance. It has been observed that the incorporation of a triazole ring with different biologically active moieties imparts potent biological properties to the molecules. Bearing in mind this observation, we designed and synthesized novel coumarin–triazole hybrids in the present research work. These synthetic compounds were assayed for their tyrosinase inhibition activity, which was further confirmed by an in silico induced fit docking (IFD) simulation.

2. Result and Discussion

2.1. Synthesis

The synthetic process of the target coumarin–triazole hybrids is depicted in Scheme 1. Briefly, to probe the impact of substitution in the aromatic part of coumarin on tyrosinase inhibitory activity, the compound 7-hydroxy-4-methylcoumarin (11; used as a precursor for further synthetic manipulation) was synthesized (70%) by the Pechmann condensation of commercially available resorcinol (10) with ethylacetoacetate by using a catalytic amount of sulfuric acid, followed by its reaction with 2-bromoacetylbromide in the presence of pyridine to afford 4-methyl-2-oxo-2H-chromen-7-yl carbonobromidate (12) (80%). Different substituted o-hydoxybenzaldehydes (13a–h) were treated with ethyl chloroacetate in the presence of K2CO3 to procure a variety of ethyl benzofuran-2-carboxylates (14a–h) (70–75%). Afterwards, substituted benzofuran-2-carbohydrazides (15a–h) (87–90%) were obtained by treating the ethyl benzofuran-2-carboxylates (14a–h) with hydrazine hydrate in MeOH. These substituted benzofuran-2-carbohydrazides (15a–h) were converted into thiosemicarbazides by using arylisothiocyanates. Various 1,2,4-triazoles (16a–h) (76–79%) were afforded by the cyclization of substituted 2-(benzofuran-2-carbonyl)hydrazine-1-sulfinimidamides in the presence of aqueous NaOH solution. To furnish the targeted coumarin–triazole hybrids (17a–h), K2CO3 was added to the solution of substituted 5-(benzofuran-2-yl)-4H-1,2,4-triazole-3-thiols (16a–h) in DCM (dichloromethane). Then, 4-methyl-2-oxo-2H-chromen-7-yl carbonobromidate (12) was added, and the reaction mixture was stirred to obtain the target compounds (17a–h) in a 62–75% yield range.

2.2. Spectral Description of the Most Potent Compound (17e)

4-Methyl-2-oxo-2H-chromen-7-yl-2-((5-(5-bromobenzofuran-2-yl)-4-(4-methoxyphenyl)-4H-1,2,4-triazol-3-yl)thio)acetate was synthesized as a coarse off-white solid. Its molecular formula/purity was ascertained by elemental analysis, and structural elucidation was attained through 1H and 13C NMR spectroscopy.
In the 1H-NMR spectrum, at δ 4.34, the signal for H-6 between S and carbonyl group was observed. Peaks for three protons of methyl groups at H-1 and H-9 were detected at δ 2.40 and δ 3.91, respectively. 2H-8 and 2H-10 resonated at δ 7.08, whereas 2H-7 and 2H-11 of the phenyl ring resonated at δ 7.31 as a singlet. Aromatic protons H-14 and H-13 reverberated as a doublet at δ 7.59 with a coupling constant (J) of 8 Hz, while proton-14 and proton-2 appeared at δ 6.42 and δ 6.25, respectively (Figure 4). The carbon scaffold of the aforesaid compound was also confirmed by 13C NMR. Signals for all the 20 carbons were detected in the spectrum, and the upfield signal at δ 34.4 confirmed the development of the methylene linker between compounds 11 and 15. The other two signals of carbons at δ 148 and δ 148 authenticated the presence of a 1,2,4-triazole ring. The substituted phenyl carbons showed their signals at δ 113, δ 128, and δ 129. In the same way, signal for carbons of the benzofuran ring appeared at δ 110, δ 116, δ 118, δ 125, δ 144, δ 152, and δ 161 (Figure 4). The benzofuran and the benzene rings in compound 17e bore the electron-donating groups Br and OMe, respectively. The spectroscopic studies confirmed the structure of 17e. Other synthetic derivatives were structurally characterized by a similar approach (Figures S1–S16).

2.3. Anti-Tyrosinase Activity of Target Compounds

All the synthesized triazole derivatives of coumarin exhibited tyrosinase inhibition activity comparable to that of the standard inhibitor, ascorbic acid (IC50 = 11.5 ± 1.00), with IC50 (half maximal inhibitory concentration) values ranging from 0.33 ± 0.08 µM to 14.06 ± 0.17 µM, as given in Table 1.
Compounds 17e, 17f, and 17g exhibited excellent potent activity, with IC50 of 0.339 ± 0.08, 3.148 ± 0.23, and 3.982 ± 0.12, respectively, while 17b and 17c showed comparatively lower enzyme inhibition activity. The substitution and position on the benzene ring of the benzofuran nucleus significantly increases or decreases the potent inhibition activity of the synthesized scaffolds 17a–h.

2.4. Structure–Activity Relationship (SAR) of Potent Anti-Tyrosinase Derivatives

The SAR (structure–activity relationship) interpretation of the present findings revealed that the halo substitution on the benzene ring manifests the promising inhibitory effects of these derivatives. Among all the synthesized triazole derivatives of coumarin, scaffold 17e with a bromine group at the benzofuran ring showed the best inhibition activity, with an IC50 = 0.339 ± 0.08 µM, which is even much higher than those of the reference inhibitory drugs, ascorbic acid (IC50 = 11.5 ± 1.0 µM) and kojic acid (IC50 = 30.34 ± 0.75 µM). The IC50 values of 17f and 17g with Cl-substituted aromatic rings were observed to be 3.148 ± 0.23 µM (%age inhibition of 36.134 ± 0.21) and 3.982 ± 0.12 µM (31.0609 ± 0.19), respectively, which are also greater than those of the frequently used standards. In a similar way, high enzyme inhibition activity was displayed by 17d (IC50 = 5.893 ± 0.09 and %age inhibition = 23.097 ± 0.13), which bears a Br-substituted aromatic ring. Moderate tyrosinase inhibitory potential (IC50 = 8.138 ± 0.13 and %age inhibition = 12.023 ± 0.21) was exhibited by 17a, which carries an unsubstituted benzofuran ring. On the other hand, compounds 17b (%age inhibition = 6.3009 ± 0.14 and IC50 = 14.062 ± 0.17) and 17c (%age inhibition = 5.110 ± 0.15 and IC50 =12.987 ± 0.32) with methoxy benzofuran substitution proved to be less active against the tested enzyme concentration. The comparison of the IC50 values of all compounds showed that not substituting and substituting the benzofuran ring with electron-donating groups such as OMe lowered the tyrosinase inhibition activity.

2.5. In Silico Modeling of Representative Potent Tyrosinase Inhibitor (17e)

The most potent coumarin–triazole hybrids, 17e and 17f, were subjected to molecular docking (IFD docking) to elaborate the vital interactions which are liable for the binding between ligand and protein. The binding energies and binding modes of the aforesaid compounds were also investigated. We used the 2Y9X (protein database code) crystal structure, in which the enzyme tyrosinase belongs to the same species of mushroom, A. bisporus, which was used in in vitro experimental studies. Tyrosinase (2Y9X) is a tetramer in which tropolone is bound to various subunits, thus having different conformation depending upon the subunits. Through cognate redocking, the dependability of the docking study was assessed. In MOE, the native tropolone ligand was redocked. To validate our docking protocol, the RMSD was calculated between the atomic coordinates of the co-crystallized and theoretical poses of the tropolone inhibitor that was present in the crystal structure (2Y9X). The self-docking result revealed a root mean square deviation (RMSD) of less than 1.5 Å between the native and redocked ligands (Figure 5).
A pyran ring with an oxo group is a common constituent in the structures of Kojic acid and most potent compounds. However, Kojic acid has hydroxyl and hydroxy methyl groups attached to the pyran ring, while 17e and 17f have a triazole ring and a benzofuran ring, along with a coumarin core. The binding interactions of the selected compounds, 17e and 17f, with the receptor site of the protein (2Y9X) were calculated. Both of the compounds showed higher binding interactions, −6.75 kcal/mol for 17e and −6.29 kcal/mol for 17f, respectively, compared with the standard IFD threshold for Kojic acid (∆G −5.25 kcal/mol), indicating a better potential of these compounds (Table 2).
According to the docked compound’s ligand–protein binding interaction study, they engage with the receptor site surrounding the copper vicinity, which could possibly be the cause of the inhibition of tyrosinase. Kojic acid was found to have prominent hydrogen-bonding (GLY-281, HIS-61, VAL-283, HIS-85, MET-280, and ASN-260) and hydrophobic (ALA-286 and HIS-263) interactions (Figure 6a–c). In the same way, compound 17e displayed hydrophobic interactions, as well as hydrogen-bonding interactions with residues. In detail, 17e showed strong bonding with GLY-281 in carbon–hydrogen bond interactions at a distance of 2.55 Å, and PHE-264 formed π hydrophobic interactions with the triazole ring and furan π-system at distances of 5.27 and 5.46 Å, respectively (Figure 7a–c). The furan π-system also interacted with VAL-248 (4.36 Å). Similarly, the methyl group on the coumarin ring displayed an alkyl hydrophobic interaction with VAL-283 (4.19 Å), HIS-263 (3.67 Å), HIS-259 (4.82 Å), and HIS-85 (5.04 Å). VAL-283 also showed a π hydrophobic interaction with the coumarin π-system at distances of 4.55 Å and 4.51 Å. Furthermore, compound 17f displayed hydrogen bonding with GlY-281 and ARG-268 at distances of 2.59 and 2.61 Å, respectively (Figure 8a–c). LEU-275 and VAL-248 formed π hydrophobic interactions with the coumarin and phenyl group of triazole at distances of 5.21 Å and 4.04 Å, respectively. Similarly, the methyl group of 17f formed alkyl hydrophobic interactions with VAL-283 (4.52Å), HIS-259 (4.77 Å), HIS-85 (5.13 Å), and HIS-263 (3.57 Å), as well as a π hydrophobic interaction with VAL-283 at distances of 4.31 Å and 4.29 Å. Additionally, the hydroxylpyranone part of Kojic acid can chelate with the Cu2+ at the active site of tyrosinase, while the coumarin core of compound 17e seemed to be involved in a π-stacking interaction with the His-263 residue, which makes a complex with one of the Cu2+ ions.
Therefore, the experimental results, identifying the aforesaid compounds (17e and 17f) as strong tyrosinase inhibitors, were corroborated by the induced fit docking analysis.

3. Materials and Methods

3.1. Chemicals and Reagents

Kojic acid and ascorbic acid were obtained from Sigma–Aldrich (St. Louis, MO, USA), while the other required chemicals were bought from local suppliers. All chemicals were purified and dried before use. A WRS-1B mp apparatus was used for melting point determination of the synthesized compounds, and the thermometer was uncorrected. For drying organic phases, anhydrous Na2SO4 was used. At 25 °C, all NMR spectra were recorded by using a Bruker 400 spectrometer (Bruker, Zurich, Switzerland) in DMSO-d6 or CDCl3, and the δ (chemical shifts) values were reported in ppm downfield from internal tetramethylsilane (TMS). J (coupling constants) are given in Hz, and the abbreviations used for the splitting patterns are s for singlet, d for doublet, t for triplet, and m for multiplet. Progress of all reaction processes was monitored by analytical technique TLC (thin-layer chromatography) using the n-hexane-to-ethyl acetate ratio, while spots were visualized under ultraviolet light.

3.2. General Synthetic Protocol for Synthesis of Substituted 4-Methyl-2-oxo-2H-chromen-7-yl-2-((5-(benzofuran-2-yl)-4H-1,2,4-triazol-3-yl)thio)acetates (17a–h)

In a solution of substituted benzofuran-based triazoles (16a–h) (1 mmol) in DCM (dichloromethane) (6 mL), K2CO3 (1.2 mmol) and 4-methyl-2-oxo-2H-chromen-7-yl carbonobromidate (12) (1.1 mmol) were added. The reaction mixture was allowed to stir at 25 °C and monitored by TLC, which indicated reaction completion after 16 h. Precipitates of the desired products (17a–h) (62–75%) were obtained upon the addition of n-hexane and distilled water. The crude products were purified via recrystallization by using ethanol.

3.2.1. 4-Methyl-2-oxo-2H-chromen-7-yl-2-((5-(benzofuran-2-yl)-4-phenyl-4H-1,2,4-triazol-3-yl)thio)acetate (17a)

  • Coarse off-white solid; yield: 65%; mp 152 °C; 1H NMR (CDCl3, 400 MHz) δ (ppm): 2.40 (s, 3H); 4.32 (s, 2H); 6.25 (s, 1H); 6.55 (s, 1H); 7.13 (s, 1H); 7.18 (d, J = 8 Hz, 1H); 7.27 (s, 1H); 7.35 (s, 1H); 7.37–7.42 (m, 3H); 7.54–7.68 (m, 6H). 13C NMR (CDCl3, 100 MHz): δ (ppm) 18.7, 34.5, 107.5, 110.2, 113.2, 114.6, 116.7, 118.0, 118.1, 124.4, 125.5, 125.6, 127.3, 127.3, 129.1, 129.28, 130.3, 130.3, 131.1, 132.7, 143.2, 147.5, 151.8, 152.8, 153.5, 154.0, 160.3, 166.3. MS m/z: 509.9 [M]+. Anal. Elem. Calc. for C28H19N3O5 S: C, 66.00: H, 3.76: N, 8.25: Found: C, 66.02: H, 3.78: N, 8.24.

3.2.2. 4-Methyl-2-oxo-2H-chromen-7-yl-2-((5-(7-methoxybenzofuran-2-yl)-4-phenyl-4H-1,2,4-triazol-3-yl)thio)acetate (17b)

  • Amorphous white solid; yield: 75%; mp 140 °C; 1H NMR (CDCl3, 400 MHz) δ (ppm): 2.40 (s, 3H); 3.81 (s, 3H); 4.34 (s, 2H); 6.25 (s, 1H); 6.77 (t, J = 20 Hz 2H); 7.05–7.12 (m, 3H); 7.17 (d, J = 12 Hz 1H); 7.41 (d, J = 8 Hz 2H); 7.57–7.62 (m, 4H). 13C NMR (CDCl3, 100 MHz): δ (ppm) 18.7, 34.5, 56.4, 108.6, 109.3, 109.4, 110.2, 114.6, 118.0, 118.1, 124.3, 125.5, 127.4, 127.5, 129.0, 130.0, 130.1, 130.6, 130.7, 133.1, 142.2, 144.5, 145.5, 148.0, 151.9, 152.8, 154.0, 160.4, 166.4. MS m/z: calcd. 539.9 [M]+. Anal. Elem. Calc. for C29H21N3O6S: C, 64.56: H, 3.92: N, 7.79: Found: C, 64.53: H, 3.93: N, 7.80.

3.2.3. 4-Methyl-2-oxo-2H-chromen-7-yl-2-((5-(7-methoxybenzofuran-2-yl)-4-(4-methoxyphenyl)-4H-1,2,4-triazol-3-yl)thio)acetate (17c)

  • Coarse off-white powder; yield, 64%; mp 137 °C; 1H NMR (CDCl3, 400 MHz) δ (ppm): 2.36 (s, 3H); 3.82 (s, 3H); 3.85 (s, 3H); 4.27 (s, 2H); 6.2 (s, 1H); 6.57 (s, 1H); 6.74 (d, J = 8 Hz, 1H); 7.0–7.08 (m, 5H); 7.13 (d, J = 8 Hz, 1H); 7.26 (d, J = 8 Hz, 2H); 7.54 (d, J = 8 Hz, 1H). 13C NMR (CDCl3, 100 MHz): δ (ppm) 18.7, 34.4, 55.7, 56.4, 108.2, 109.0, 110.2, 113.8, 114.6, 114.6, 115.2, 115.3, 118.0, 124.2, 125.5, 125.5, 128.6, 128.6, 129.1, 142.5, 144.5, 145.5, 148.3, 151.9, 152.1, 152.8, 154.0, 160.4, 161.1, 166.5. MS m/z: 569.9 [M]+. Anal. Elem. Calc. for C30H23N3O7S: C, 63.26: H, 4.07: N, 7.38: Found: C, 63.25: H, 4.09: N, 7.39.

3.2.4. 4-Methyl-2-oxo-2H-chromen-7-yl-2-((5-(5-bromobenzofuran-2-yl)-4-phenyl-4H-1,2,4-triazol-3-yl)thio)acetate (17d)

  • Coarse white powder; yield, 70%; mp 232 °C; 1H NMR (DMSO-d6, 400 MHz) δ (ppm): 2.49 (s, 3H); 4.45 (s, 2H); 6.41 (s, 1H); 6.50 (s, 1H); 7.23 (d, J = 28 Hz 2H); 7.51–7.69 (m, 7 H); 7.87 (s, 2H). 13C NMR (DMSO-d6, 100 MHz): δ (ppm) 18.6, 34.5, 107.0, 110.2, 113.9, 114.3, 118.5, 118.5, 125.0, 125.0, 125.0, 127.1, 128.0, 128.1, 128.1, 129.3, 130.7, 133.3, 133.3, 144.3, 144.3, 144.5, 147.5, 153.0, 153.3, 153.3, 160.0, 167.4. MS m/z: 587.6 [M]+. Anal. Elem. Calc. for C28H18BrN3O5S: C, 57.15: H, 3.08: N, 7.14: Found: C, 57.17: H, 3.09: N, 7.17.

3.2.5. 4-Methyl-2-oxo-2H-chromen-7-yl-2-((5-(5-bromobenzofuran-2-yl)-4-(4-methoxyphenyl)-4H-1,2,4-triazol-3-yl)thio)acetate (17e)

  • Coarse gray solid; yield, 62%; mp 220 °C 1H NMR (CDCl3, 400 MHz) δ (ppm): 2.40 (s, 3H); 3.91 (s, 3H); 4.34 (s, 2H); 6.25 (s, 1H); 6.42 (s, 1H); 7.08 (d, J = 8 Hz, 2H); 7.13 (s, 1H); 7.17 (d, J = 8 Hz, 1H); 7.31 (d, J = 8 Hz, 3H); 7.39 (d, J = 8 Hz, 1H); 7.59 (d, J = 8 Hz, 2H). 13C NMR (CDCl3, 100 MHz): δ (ppm) 18.7, 34.6, 55.7, 106.8, 110.2, 113.2, 113.2, 114.6, 115.4, 116.6, 118.0, 118.1, 124.2, 125.0, 125.5, 128.6, 129.1, 129.2, 143.6, 148.0, 148.0, 151.8, 152.7, 152.8, 153.5, 154.0, 160.3, 161.3, 166.4. MS m/z: 617.6 [M]+. Anal. Elem. Calc. for C29H20BrN3O6S: C, 56.62: H, 3.26: N, 6.79: Found: C, 56.65: H, 3.27: N, 6.80.

3.2.6. 4-Methyl-2-oxo-2H-chromen-7-yl-2-((5-(5-chlorobenzofuran-2-yl)-4-phenyl-4H-1,2,4-triazol-3-yl)thio)acetate (17f)

  • Amorphous white solid; yield, 72%; mp 226 °C; 1H NMR (DMSO-d6, 400 MHz) δ (ppm): 2.49 (s, 3H); 4.45 (s, 2H); 6.41 (s, 1H); 6.50 (s, 1H); 7.23 (t, J = 28 Hz, 1H); 7.38 (d, J = 12 Hz, 2H); 7.57–7.85 (m, 7H); 7.88 (d, J = 12 Hz, 1H). 13C NMR (DMSO-d6, 100 MHz): δ (ppm) 18.6, 34.5, 107.1, 110.2, 113.4, 114.3, 114.3, 118.5, 122.0, 126.6, 126.6, 126.6, 127.1, 128.0, 128.5, 129.1, 129.1, 130.7, 131.4, 133.32, 144.5, 144.5, 147.5, 152.6, 152.6, 153.9, 160.0, 167.4. MS m/z: 543.9 [M]+. Anal. Elem. Calc. for C28H18ClN3O5S: C, 61.82: H, 3.34: N, 7.72: Found: C, 61.84: H, 3.35: N, 7.70.

3.2.7. 4-Methyl-2-oxo-2H-chromen-7-yl2-((5-(5-chlorobenzofuran-2-yl)-4-(4-methoxyphenyl)-4H-1,2,4-triazol-3-yl)thio)acetate (17g)

  • Coarse off-white solid; yield, 67%; mp 200 °C; 1H NMR (CDCl3, 400 MHz) δ (ppm): 2.32 (s, 3H); 3.68–4.12 (m, 3H); 4.12 (s, 2H); 6.01 (s, 1H); 6.74 (t, J = 16 Hz, 2H); 6.83–6.92 (m, 1H); 7.07 (t, J = 16 Hz, 2H); 7.15–7.30 (m, 5H); 7.35 (t, J = 24 Hz 1H). 13C NMR (CDCl3, 100 MHz): δ (ppm) 18.6, 21.0, 22.6, 31.5, 55.4, 60.4, 103.3, 110.1, 110.7, 112.7, 113.5, 114.3, 115.4, 115.6, 118.0, 121.2, 125.6, 125.6, 126.5, 128.6, 128.9, 128.9, 152.8, 152.8, 153.4, 155.0, 160.9, 162.2, 171.3. MS m/z: 571.9 [M]+. Anal. Elem. Calc. for C29H20ClN3O6S: C, 60.68: H, 3.51: N, 7.32: Found: C, 60.71: H, 3.52: N, 7.34.

3.2.8. 4-Methyl-2-oxo-2H-chromen-7-yl-2-((5-(naphtho[2,1-b]furan-2-yl)-4-phenyl-4H-1,2,4-triazol-3-yl)thio)acetate (17h)

  • Yellow solid; yield, 63%; mp 218 °C; 1H NMR (CDCl3, 400 MHz) δ (ppm): 2.35 (s, 3H); 4.32 (s, 2H); 6.19 (s, 1H); 7.08 (s, 1H); 7.14–7.21 (m, 3H); 7.42 (d, J = 8 Hz, 3H); 7.48 (t, J = 16 Hz 1H); 7.54–7.63 (m, 5H); 7.66–7.87 (m, 2H). 13C NMR (CDCl3, 100 MHz): δ (ppm) 18.7, 34.5, 110.2, 110.2, 112.2, 112.2, 114.6, 118.0, 122.8, 123.2, 125.7, 125.6, 126.9, 126.9, 127.8, 127.8, 127.8, 128.8, 128.8, 128.8, 128.8, 130.3, 130.4, 131.1, 132.9, 140.98, 151.8, 152.8, 152.8, 154.0, 160.4, 166.3. MS m/z: 559.9 [M]+. Anal. Elem. Calc. for C32H21ClN3O5S: C, 68.68: H, 3.78: N, 7.51: Found: C, 68.70: H, 3.76: N, 7.52.

3.3. Tyrosine Assay of Inhibitory Activity of Target Compounds

The synthesized coumarin–triazole hybrids were subjected to spectrophotometric assay for tyrosinase by employing Ellman’s method [55,56]. The tyrosine enzyme was extracted from Bacillus subtilis NCTC 10400. The anti-tyrosinase potential of all the coumarin–triazole hybrids was screened by using L-DOPA (levodopa) as the substrate. All the coumarin derivatives were dissolved in DMSO. A 2.0% solution of the test compound was made in DMSO, and the stock solution was further diluted by using phosphate buffer at pH 6.8. The coumarin derivatives along with the tyrosine enzyme (0.5 mg/mL) were pre-incubated for 10 min in buffer at 25 °C. Pre-incubation of tyrosinase and coumarin derivative was followed by the addition of levodopa (0.5 mM), and the reaction was monitored by absorbance measurement at 475 nm. The IC50 values were calculated by interpolation of the dose–response curves. The following formula was applied to calculate the percentage inhibition of tyrosinase:
%age Inhibition = (B − S/B) × 100
where S and B are the absorbance values for the sample and blank, respectively. For comparison, we used ascorbic acid as the reference inhibitor.

3.4. In Silico Modeling Method

For IFD (induced fit docking), the most potent compound, 17e, was chosen. The Molecular Operating Environment (MOE 2015) [57] was used for all docking operations. The desired compound (17e) was produced by using the ChemDraw program. In the IFD simulation, Kojic acid was used as the standard, and its 3D conformer (CID: 3840) was taken from PubChem. The Protein Data Bank (PDB) [58] provided the crystalline structure of tyrosinase (2Y9X), which was utilized as the receptor for use in IFD. The MOE Quick-Prep tool was utilized for preparing the molecular structures of the ligand and protein. The docking system’s energy consumption was reduced by using the standard Amber10:EHT forcefield with a gradient of 0.1. The following methods were utilized for assessment: London-dG, WSA/GBVI scoring, Induced Fit refinement, and Triangular Matcher placement. To verify the docking approach, cognate redock was applied to the native ligand. The analysis of the ligand–protein interactions was carried out in BIOVIA Discovery Studio 2021.

4. Conclusions

A library of coumarin–triazole hybrids was synthesized by the coupling of different benzofuran-based triazoles with 7-hydroxy-4-methylcoumarin. The synthesized coumarin derivatives with various electron-donating and electron-withdrawing groups were characterized by various analytical techniques. The anti-tyrosinase activity of the synthesized coumarin–triazole hybrids was assessed through in vitro screening. A computational study was also carried out to verify the findings interpreted from the in vitro screening of anti-tyrosinase activity. All the synthesized compounds were found more active against the tyrosinase enzyme than Kojic acid and ascorbic acid (standards). The in vitro study indicated that in the library of derived compounds, 17e showed excellent anti-tyrosinase activity, with an IC50 = 0.339 ± 0.08. Moreover, 17f exhibited remarkable potency, with an IC50 of 3.148 ± 0.23 μM, showing that the presence of EDG on the aromatic ring of the synthesized compounds improved anti-tyrosinase activity compared with compounds with unsubstituted aromatic rings. Therefore, the presence of EWG (Br and Cl) on the benzofuran moiety of the coumarin scaffold appears to modify the pharmacological behavior of these coumarin–triazole hybrids. The mode of action of compounds 17e and 17f against tyrosinase was determined by docking studies, and the results of the docking analysis of the mentioned compounds were in accordance with the biological diagnostic results, confirming that these hybrids could be established as lead compounds.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/ph17040532/s1, Figures S1–S16: 1H and 13C NMR spectra of compounds 17a–h.

Author Contributions

Conceptualization: A.F.Z.; Biological research: S.K. and H.T.; Writing—original draft preparation: R.K.; Writing—review and editing: A.F.Z. and M.A.B. Synthesis: R.K.; Resources: M.A.B. and H.T.; Funding acquisition: M.A.B. All authors have read and agreed to the published version of the manuscript.

Funding

Researchers supporting project number (RSPD2024R740) King Saud University, Riyadh, Saudi Arabia.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

All the data are contained within the article and the Supplementary Materials.

Acknowledgments

We are thankful for the Researchers supporting project number (RSPD2024R740), King Saud University, Riyadh, Saudi Arabia.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Chen, H.-Y.; Yeh, Y.-C. Detection of tyrosine and monitoring tyrosinase activity using an enzyme cascade-triggered colorimetric reaction. RSC. Adv. 2020, 10, 29745–29750. [Google Scholar] [CrossRef] [PubMed]
  2. Cai, H.; Wen, H.; Li, J.; Lu, L.; Zhao, W.; Jiang, X.; Bai, R. Small-molecule agents for treating skin diseases. Eur. J. Med. Chem. 2024, 268, 116269. [Google Scholar] [CrossRef] [PubMed]
  3. Kim, H.D.; Choi, H.; Abekura, F.; Park, J.Y.; Yang, W.S.; Yang, S.H.; Kim, C.H. Naturally-occurring tyrosinase inhibitors classified by enzyme kinetics and copper chelation. Int. J. Mol. Sci. 2023, 24, 8226. [Google Scholar] [CrossRef] [PubMed]
  4. Irfan, A.; Zahoor, A.F.; Kamal, S.; Hassan, M.; Kloczkowski, A. Ultrasonic-Assisted Synthesis of Benzofuran Appended Oxadiazole Molecules as Tyrosinase Inhibitors: Mechanistic Approach through Enzyme Inhibition, Molecular Docking, Chemoinformatics, ADMET and Drug-Likeness Studies. Int. J. Mol. Sci. 2022, 23, 10979. [Google Scholar] [CrossRef] [PubMed]
  5. Nagatsu, T.; Nakashima, A.; Watanabe, H.; Ito, S.; Wakamatsu, K. Neuromelanin in Parkinson’s Disease: Tyrosine Hydroxylase and Tyrosinase. Int. J. Mol. Sci. 2022, 23, 4176. [Google Scholar] [CrossRef]
  6. Fang, X.; Dai, L.; Ding, T.M.; Zhu, Y.; Zan, J.F.; Chen, L.L.; Ding, X.P.; Liu, J.F. Screening and identification of tyrosinase inhibitors in edible plant materials by on-line UPLC-enzyme reactor coupled with UHPLC-FTMS. Food Chem. 2023, 403, 134331. [Google Scholar] [CrossRef] [PubMed]
  7. Xue, S.; Li, Z.; Ze, X.; Wu, X.; He, C.; Shuai, W.; Marlow, M.; Chen, J.; Scurr, D.; Zhu, Z.; et al. Design, synthesis, and biological evaluation of novel hybrids containing dihydrochalcone as tyrosinase inhibitors to treat skin hyperpigmentation. J. Med. Chem. 2023, 66, 5099–5117. [Google Scholar] [CrossRef] [PubMed]
  8. Hassan, M.; Shahzadi, S.; Kloczkowski, A. Tyrosinase inhibitors naturally present in plants and synthetic modifications of these natural products as anti-melanogenic agents: A review. Molecules 2023, 28, 378. [Google Scholar] [CrossRef] [PubMed]
  9. Nagatsu, T.; Nakashima, A.; Watanabe, H.; Ito, S.; Wakamatsu, K.; Zucca, F.A.; Zecca, L.; Youdim, M.; Wulf, M.; Riederer, P.; et al. The role of tyrosine hydroxylase as a key player in neuromelanin synthesis and the association of neuromelanin with Parkinson’s disease. J. Neural Transm. 2023, 130, 611–625. [Google Scholar] [CrossRef]
  10. Marieshwari, B.N.; Bhuvaragavan, S.; Sruthi, K.; Mullainadhan, P.; Janarthanan, S. Insect phenoloxidase and its diverse roles: Melanogenesis and beyond. J. Comp. Physiol. B 2023, 193, 1–23. [Google Scholar] [CrossRef]
  11. Carradori, S.; Melfi, F.; Rešetar, J.; Şimşek, R. Tyrosinase enzyme and its inhibitors: An update of the literature. Metalloenzymes 2024, 533–546. [Google Scholar] [CrossRef]
  12. Vaezi, M. Structure and inhibition mechanism of some synthetic compounds and phenolic derivatives as tyrosinase inhibitors: Review and new insight. J. Biomol. Struct. Dyn. 2023, 41, 4798–4810. [Google Scholar] [CrossRef] [PubMed]
  13. Baber, M.A.; Crist, C.M.; Devolve, N.L.; Patrone, J.D. Tyrosinase Inhibitors: A Perspective. Molecules 2023, 28, 5762. [Google Scholar] [CrossRef] [PubMed]
  14. Loizzo, R.; Tundis, R.; Menichini, F. Natural and Synthetic Tyrosinase Inhibitors as Antibrowning Agents: An Update. Compr. Rev. Food Sci. Food Saf. 2012, 4, 378–398. [Google Scholar] [CrossRef]
  15. Chandarajoti, K.; Kara, J.; Suwanhom, P.; Nualnoi, T.; Puripattanavong, J.; Lee, V.S.; Tipmanee, V.; Lomlim, L. Synthesis and evaluation of coumarin derivatives on antioxidative, tyrosinase inhibitory activities, melanogenesis, and in silico investigations. Sci. Rep. 2024, 14, 5535. [Google Scholar] [CrossRef] [PubMed]
  16. Bhosale, R.S.; Sarda, S.R.; Ardhapure, S.S.; Jadhav, W.N.; Bhusare, S.R.; Pawar, R.P. An efficient protocol for the synthesis of quinoxaline derivatives at room temperature using molecular iodine as the catalyst. Tetrahedron Lett. 2005, 46, 7183–7186. [Google Scholar] [CrossRef]
  17. Irfan, A.; Faisal, S.; Zahoor, A.F.; Noreen, R.; Al-Hussain, S.A.; Tuzun, B.; Javaid, R.; Elhenawy, A.A.; Zaki, M.E.A.; Ahmad, S.; et al. In Silico Development of Novel Benzofuran-1,3,4-Oxadiazoles as Lead Inhibitors of M. tuberculosis Polyketide Synthase 13. Pharmaceuticals 2023, 16, 829. [Google Scholar] [CrossRef]
  18. Banik, B.K.; Sahoo, B.M.; Kumar, B.V.; Panda, K.C.; Jena, J.; Mahaputra, M.K.; Borah, P. Green Synthetic Approach: An Efficient eco-friendly tool for synthesis of biologically active oxadiazole derivatives. Molecules 2021, 26, 1163. [Google Scholar] [CrossRef]
  19. Ahmad, S.; Khan, M.; Alam, A.; Ajmal, A.; Wadood, A.; Khan, A.; AlAsmari, A.F.; Alharbi, M.; Alshammari, A.; Shakoor, A. Novel flurbiprofen clubbed oxadiazole derivatives as potential urease inhibitors and their molecular docking study. RSC Adv. 2023, 13, 25717–25728. [Google Scholar] [CrossRef]
  20. Shahzadi, I.; Zahoor, A.F.; Rasul, A.; Rasool, N.; Raza, Z.; Faisal, S.; Parveen, B.; Kamal, S.; Zia-ur-Rehman, M.; Zahid, F.M. Synthesis, anticancer, and computational studies of 1, 3, 4-oxadiazole-purine derivatives. J. Heterocycl. Chem. 2020, 57, 2782–2794. [Google Scholar] [CrossRef]
  21. Shahzadi, I.; Zahoor, A.F.; Rasul, A.; Mansha, A.; Ahmad, S.; Raza, Z. Synthesis, hemolytic studies, and in silico modeling of novel acefylline–1, 2, 4-triazole hybrids as potential anti-cancer agents against MCF-7 and A549. ACS Omega 2021, 6, 11943–11953. [Google Scholar] [CrossRef] [PubMed]
  22. Korlyukov, A.A.; Stash, A.I.; Romanenko, A.R.; Trzybiński, D.; Woźniak, K.; Vologzhanina, A.V. Ligand-Receptor Interactions of Lamivudine: A View from Charge Density Study and QM/MM Calculations. Biomedicines 2023, 11, 743. [Google Scholar] [CrossRef] [PubMed]
  23. Hatami, M.; Basri, Z.; Sakhvidi, B.K.; Mortazavi, M. Thiadiazole—A promising structure in design and development of anti-Alzheimer agents. Int. Immunopharmacol. 2023, 118, 110027. [Google Scholar] [CrossRef]
  24. Rasgania, J.; Gavadia, R.; Nimesh, S.; Loveleen, L.; Mor, S.; Singh, D.; Jakhar, K. Synthesis of isatin-tagged thiadiazoles as anti-breast cancer leads: In-vitro and in-silico investigations. J. Mol. Struct. 2023, 1294, 136464. [Google Scholar] [CrossRef]
  25. Taiwo, F.O.; Abioye, O.E.; Obafemi, C.A.; Akinpelu, D.A. Synthesis and Antibacterial Potency of Some 3-methyl-2-oxo-1,2-dihydroquinoxaline-6-sulfonohydrazone Derivatives. J. Adv. Microb. 2023, 23, 56–70. [Google Scholar] [CrossRef]
  26. Akhtar, R.; Zahoor, A.F.; Rasul, A.; Khan, S.G.; Ali, K.G. In-vitro cytotoxic evaluation of newly designed ciprofloxacinoxadiazole hybrids against human liver tumor cell line (Huh7). Pak. J. Pharm. Sci. 2021, 34, 1143–1148. [Google Scholar]
  27. Li, Q.; Yang, Y.; Li, Y.; Mi, Y.; Ma, X.; Jiang, A.; Guo, Z. Enhanced biological activities of coumarin-functionalized polysaccharide derivatives: Chemical modification and activity assessment. Int. J. Biol. Macromol. 2023, 253, 126691. [Google Scholar] [CrossRef]
  28. Sadgir, N.V.; Adole, V.A.; Dhonnar, S.L.; Jagdale, B.S. Synthesis and biological evaluation of coumarin appended thiazole hybrid heterocycles: Antibacterial and antifungal study. J. Moe. Struct. 2023, 1293, 136229. [Google Scholar] [CrossRef]
  29. Yang, X.C.; Zeng, C.M.; Avula, S.R.; Peng, X.M.; Geng, R.X.; Zhou, C.H. Novel coumarin aminophosphonates as potential multitargeting antibacterial agents against Staphylococcus aureus. Eur. J. Med. Chem. 2023, 245, 114891. [Google Scholar] [CrossRef]
  30. Patel, K.B.; Mukherjee, S.; Bhatt, H.; Rajani, D.; Ahmad, I.; Patel, H.; Kumari, P. Synthesis, docking, and biological investigations of new coumarin-piperazine hybrids as potential antibacterial and anticancer agents. J. Mol. Struct. 2023, 1276, 134755. [Google Scholar] [CrossRef]
  31. Rai, U.S.; Isloor, A.M.; Shetty, P.; Vijesh, A.M.; Prabhu, N.; Isloor, S. Novel Chromeno [2,3-b]-pyrimidine Derivatives as Potential Anti-Microbial Agents. Eur. J. Med. Chem. 2010, 45, 2695–2699. [Google Scholar]
  32. Kostova, I. Coumarins as Inhibitors of HIV Reverse Transcriptase. Curr. HIV Res. 2006, 4, 347–363. [Google Scholar] [CrossRef] [PubMed]
  33. Ramsis, T.M.; Ebrahim, M.A.; Fayed, E.A. Synthetic Coumarin Derivatives with Anticoagulation and Antiplatelet Aggregation Inhibitory Effects. Med. Chem. Res. 2023, 32, 2269–2278. [Google Scholar] [CrossRef]
  34. Claudio, B.; Adriana, M.; Francesco, M.; Keith, W.; Monica, B.; Antonino, S.; Santi, S. New Coumarin-Based Anti-Inflammatory Drug: Putative Antagonist of the Integrins aLb2 and aMb2. J. Pharm. Pharmacol. 2008, 60, 1473–1479. [Google Scholar]
  35. Matos, M.J.; Varela, C.; Vilar, S.; Hripcsak, G.; Borges, F.; Santana, L.; Uriarte, E.; Fais, A.; Petrillo, A.D.; Pintus, F.; et al. Design and discovery of tyrosinase inhibitors based on a coumarin scaffold. RSC Adv. 2015, 5, 94227–94235. [Google Scholar] [CrossRef]
  36. Matin, P.; Matin, M.; Rehaman, R.; Hadda, T.B.; Almalki, F.A.; Mehmud, S.; Ghoneim, M.M.; Maha, A.; Sultan, A. Triazoles and Their Derivatives: Chemistry, Synthesis, and Therapeutic Applications. Mol. Diagn. Ther. 2022, 9, 864286. [Google Scholar] [CrossRef] [PubMed]
  37. Bhat, K.S.; Poojary, B.; Prasad, D.J.; Naik, P.; Holla, B.S. Synthesis and Antitumor Activity Studies of Some New Fused 1, 2, 4-triazole Derivatives Carrying 2,4-dichloro-5-fluorophenyl Moiety. Eur. J. Med. Chem. 2009, 44, 5066–5070. [Google Scholar] [CrossRef] [PubMed]
  38. Aggarwal, N.; Kumar, R.; Dureja, P.; Khurana, J.M. Synthesis, Antimicrobial Evaluation and QSAR analysis of Novel Nalidixic Acid Based 1, 2, 4-triazole Derivatives. Eur. J. Med. Chem. 2021, 46, 4089–4099. [Google Scholar] [CrossRef]
  39. Divar, M.; Tadayyon, S.; Khoshneviszadeh, M.; Pirhadi, S.; Attarroshan, M.; Mobaraki, K.; Damghani, T.; Mirfazli, S.; Edraki, N. Benzyl-Triazole Derivatives of Hydrazinecarbothiamide Derivatives as Potent Tyrosinase Inhibitors: Synthesis, Biological Evaluation, Structure-Activity Relationship and Docking Study. Chem. Sel. 2023, 8, e202203382. [Google Scholar] [CrossRef]
  40. Najafi, Z.; Ebadi, A.; Chehardoli, G.; Ziaei, M.; Akbarzadeh, T.; Saeedi, M.; Gholamhoseini, P.; Mahdavi, M. Design, synthesis, in vitro, and in silico studies of novel benzylidene 6-methoxy-1-tetralone linked to benzyloxy and benzyl-1, 2, 3-triazole rings as potential tyrosinase inhibitors. J. Mol. Struct. 2023, 1271, 134018. [Google Scholar] [CrossRef]
  41. Gao, F.; Wang, T.; Xiao, J.; Huang, G. Antibacterial Activity Study of 1, 2, 4-triazole Derivatives. Eur. J. Med. Chem. 2019, 173, 274–281. [Google Scholar] [CrossRef] [PubMed]
  42. Faiz, S.; Zahoor, A.F.; Ajmal, M.; Kamal, S.; Ahmad, S.; Abdelgawad, A.M.; Elnaggar, M.E. Design, Synthesis, Antimicrobial Evaluation, and Laccase Catalysis Effect of Novel Benzofuran—Oxadiazole and Benzofuran–triazole hybrids. J. Heterocycl. Chem. 2019, 56, 2839–2852. [Google Scholar] [CrossRef]
  43. Akın, S.; Demir, E.A.; Colak, A.; Kolcuoglu, Y.; Yildirim, N.; Bekircan, O. Synthesis, Biological Activities and Molecular Docking Studies of Some Novel 2,4,5- trisubstituted-1,2,4-triazole-3-one Derivatives as Potent Tyrosinase Inhibitors. J. Mol. Struct. 2019, 1175, 280–286. [Google Scholar] [CrossRef]
  44. Landge, S.; Philp, J.; Ugboya, A.; Graves, I.; Fasusi, E.; Jordan, K.; Aiken, K.; Sittaramane, V. Evaluation of ortho-substituted Bis-Functionalized Triazoles as Tyrosinase Inhibitors: Modulating Dopamine Synthesis and Behavior in Zebrafish. Med. Chem. Res. 2024, 33, 651–662. [Google Scholar] [CrossRef]
  45. Wood, W.J.L.; Patterson, A.W.; Tsuruoka, H.; Jain, R.K.; Ellman, J.A. Substrate Activity Screening: A Fragment-based Method for the Rapid Identification of Non peptidic Protease Inhibitors. J. Am. Chem. Soc. 2005, 127, 15521. [Google Scholar] [CrossRef] [PubMed]
  46. Apperley, K.Y.P.; Roy, I.; Saucier, V.; Brunet-Filion, N.; Piscopo, S.P.; Pardin, C.; De Francesco, E.; Hao, C.; Keillor, J.W. Development of New Scaffolds as Reversible Tissue Transglutaminase Inhibitors, with Improved Potency or Resistance to Glutathione Addition. Med. Chem. Comm. 2017, 8, 338. [Google Scholar] [CrossRef] [PubMed]
  47. Anand, N.; Jaiswal, N.; Pandey, S.K.; Srivastava, A.K.; Tripathi, R.P. Application of Click Chemistry Towards an Efficient Synthesis of 1, 2, 3-1H-triazolyl Glycohybrids as Enzyme Inhibitors. Carbohydr. Res. 2011, 346, 16. [Google Scholar] [CrossRef]
  48. Pardin, C.; Pelletier, J.N.; Lubell, W.D.; Keillor, J.W. Cinnamoyl inhibitors of tissue transglutaminase. J. Org. Chem. 2008, 73, 5766–5775. [Google Scholar] [CrossRef]
  49. Fan, Y.L.; Ke, X.; Liu, M. Coumarin–triazole hybrids and their biological activities. J. Heterocycl. Chem. 2018, 55, 791–802. [Google Scholar] [CrossRef]
  50. Liu, J.; Wu, F.; Chen, L.; Zhao, L.; Zhao, Z.; Wang, M.; Lei, S. Biological Evaluation of Coumarin Derivatives as Mushroom Tyrosinase Inhibitors. Food. Chem. 2012, 135, 2872. [Google Scholar] [CrossRef]
  51. Fais, A.; Corda, M.; Era, B.; Fadda, M.B.; Matos, M.J.; Quezada, E.; Santana, L.; Picciau, C.; Podda, G.; Delogu, G. Tyrosinase Inhibitor Activity of Coumarin-Resveratrol Hybrids. Molecules 2009, 14, 2514–2520. [Google Scholar] [CrossRef] [PubMed]
  52. Nunes, J.A.; Araújo, R.S.A.d.; Silva, F.N.d.; Cytarska, J.; Łączkowski, K.Z.; Cardoso, S.H.; Mendonça-Júnior, F.J.B.; Silva-Júnior, E.F.d. Coumarin-based compounds as inhibitors of tyrosinase/tyrosine hydroxylase: Synthesis, kinetic studies, and in silico approaches. Int. J. Mol. Sci. 2023, 24, 5216. [Google Scholar] [CrossRef] [PubMed]
  53. Lu, L.; Zhang, X.; Kang, Y.; Xiong, Z.; Zhang, K.; Xu, X.; Bai, L.; Li, H. Novel Coumarin Derivatives as Potential Tyrosinase Inhibitors: Synthesis, Binding Analysis and Biological Evaluation. Arab. J. Chem. 2023, 16, 104724. [Google Scholar] [CrossRef]
  54. Ivasiv, V.; Viktoriya, R.; Claudia, A.; Ana, E.; Gonçalves, M.R.; Maria, L. Molecular Hybridization as a Tool for Designing Multitarget Drug Candidates for Complex Diseases. Curr. Top. Med. Chem. 2019, 19, 1694–1711. [Google Scholar] [CrossRef] [PubMed]
  55. Cetinkaya, Y.; Göçer, H.; Göksu, S.; Gülçin, I. Synthesis and Carbonic Anhydrase Isoenzymes I and II Inhibitory Effects of Novel Benzylamine Derivatives. J. Enzym. Inhib. Med. Chem. 2014, 29, 168–174. [Google Scholar] [CrossRef]
  56. Ellman, G.L.; Courtney, K.D.; Andres, J.V.; Featherstone, R.M. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol. 1961, 7, 88–95. [Google Scholar] [CrossRef] [PubMed]
  57. Zhong, H.; Tran, L.M.; Stang, J.L. Induced-fit Docking Studies of the Active and Inactive States of Protein Tyrosine Kinases. J. Mol. Graph. Model. 2009, 28, 336–346. [Google Scholar] [CrossRef] [PubMed]
  58. Ismaya, W.T.; Rozeboom, H.J.; Weijn, A.; Mes, J.J.; Fusetti, F.; Wichers, H.J.; Dijkstra, B.W. Crystal Structure of Agaricus Bisporus Mushroom Tyrosinase: Identity of the Tetramer Subunits and Interaction with Tropolone. Biochemistry 2011, 50, 5477–5486. [Google Scholar] [CrossRef]
Pharmaceuticals 17 00532 g001
Figure 1. Naturally occurring tyrosinase inhibitors (1–4).
Figure 1. Naturally occurring tyrosinase inhibitors (1–4).
Pharmaceuticals 17 00532 g001
Pharmaceuticals 17 00532 g002
Figure 2. Some commonly used drugs having coumarin scaffolds.
Figure 2. Some commonly used drugs having coumarin scaffolds.
Pharmaceuticals 17 00532 g002
Pharmaceuticals 17 00532 g003
Figure 3. Potent tyrosinase inhibitor with coumarin core.
Figure 3. Potent tyrosinase inhibitor with coumarin core.
Pharmaceuticals 17 00532 g003
Pharmaceuticals 17 00532 sch001
Scheme 1. Synthetic strategy for the synthesis of coumarin derivatives (17a–h). Reagents and conditions: (a) Ethyl acetoacetate and H2SO4; 25 °C. (b) 2-Bromoacetyl bromide, pyridine, and CHCl3; r.t. (c) Ethyl chloroacetate, DMF, and K2CO3; 90–95 °C. (d) Hydrazine hydrate and methanol; r.t. (e) NaOH, and H2O; reflux. (f) 12, K2CO3, and DCM; r.t.
Scheme 1. Synthetic strategy for the synthesis of coumarin derivatives (17a–h). Reagents and conditions: (a) Ethyl acetoacetate and H2SO4; 25 °C. (b) 2-Bromoacetyl bromide, pyridine, and CHCl3; r.t. (c) Ethyl chloroacetate, DMF, and K2CO3; 90–95 °C. (d) Hydrazine hydrate and methanol; r.t. (e) NaOH, and H2O; reflux. (f) 12, K2CO3, and DCM; r.t.
Pharmaceuticals 17 00532 sch001
Pharmaceuticals 17 00532 g004
Figure 4. 1HNMR (A) and 13CNMR (B) interpretations of representative derivative 17e.
Figure 4. 1HNMR (A) and 13CNMR (B) interpretations of representative derivative 17e.
Pharmaceuticals 17 00532 g004
Pharmaceuticals 17 00532 g005
Figure 5. Induced fit docking between redocked (blue) and native ligand (green) validated by RMSD.
Figure 5. Induced fit docking between redocked (blue) and native ligand (green) validated by RMSD.
Pharmaceuticals 17 00532 g005
Pharmaceuticals 17 00532 g006aPharmaceuticals 17 00532 g006b
Figure 6. (a) Two-dimensional interaction of standard Kojic acid with binding pocket of 2Y9X. (b) Three-dimensional ligand–protein hydrogen-bonding interactions of standard Kojic acid. (c) Three-dimensional ligand–protein hydrogen-bonding interactions of standard Kojic acid.
Figure 6. (a) Two-dimensional interaction of standard Kojic acid with binding pocket of 2Y9X. (b) Three-dimensional ligand–protein hydrogen-bonding interactions of standard Kojic acid. (c) Three-dimensional ligand–protein hydrogen-bonding interactions of standard Kojic acid.
Pharmaceuticals 17 00532 g006aPharmaceuticals 17 00532 g006b
Pharmaceuticals 17 00532 g007aPharmaceuticals 17 00532 g007b
Figure 7. (a) Two-dimensional interaction of anti-tyrosinase agent 17e with active site of 2Y9X. (b) Docking pose of potent anti-tyrosinase agent 17e at active site of tropolone hydrophobic cavity of 2Y9X showing hydrogen-bonding interactions. (c) Docking pose of potent anti-tyrosinase agent 17e at active site of tropolone hydrophobic cavity of 2Y9X showing hydrophobic interactions.
Figure 7. (a) Two-dimensional interaction of anti-tyrosinase agent 17e with active site of 2Y9X. (b) Docking pose of potent anti-tyrosinase agent 17e at active site of tropolone hydrophobic cavity of 2Y9X showing hydrogen-bonding interactions. (c) Docking pose of potent anti-tyrosinase agent 17e at active site of tropolone hydrophobic cavity of 2Y9X showing hydrophobic interactions.
Pharmaceuticals 17 00532 g007aPharmaceuticals 17 00532 g007b
Pharmaceuticals 17 00532 g008aPharmaceuticals 17 00532 g008b
Figure 8. (a) Two-dimensional interaction diagram of compound 17f with active site of tyrosinase (2Y9X). (b) Hydrogen-bonding interactions of 17f with binding sites of 2Y9X. (c) Hydrophobic interactions of 17f with binding sites of 2Y9X.
Figure 8. (a) Two-dimensional interaction diagram of compound 17f with active site of tyrosinase (2Y9X). (b) Hydrogen-bonding interactions of 17f with binding sites of 2Y9X. (c) Hydrophobic interactions of 17f with binding sites of 2Y9X.
Pharmaceuticals 17 00532 g008aPharmaceuticals 17 00532 g008b
Table 1. Inhibitory activities of title compounds 17a–h against tyrosinase.
Table 1. Inhibitory activities of title compounds 17a–h against tyrosinase.
Sr. No.Target CompoundR1R2%Age InhibitionIC50 (µM) a
117aHC6H512.02 ± 0.218.13 ± 0.13
217b7-OMeC6H56.30 ± 0.1414.06 ± 0.17
317c7-OMe4-OMeC6H45.11 ± 0.1512.98 ± 0.32
417d5-BrC6H523.09 ± 0.135.89 ± 0.09
517e5-Br4-OMeC6H430.85 ± 0.150.33 ± 0.08
617f5-ClC6H536.13 ± 0.213.14 ± 0.23
717g5-Cl4-OMeC6H431.060 ± 0.193.98 ± 0.12
817hFused C6H4C6H530.62 ± 0.335.13 ± 0.05
10Ascorbic acid (standard) 58.66 ± 1.0011.5 ± 1.00
11Kojic acid
(standard)		 6.79 ± 0.5830.34 ± 0.75
a Values are given as means ± SEs (n = 3).
Table 2. Ligand–receptor interaction study.
Table 2. Ligand–receptor interaction study.
Interaction StudyKojic AcidCompound 17eCompound 17f
Docking score (kcal/mol)−5.25−6.75−6.29
Ligand–receptor interactionVAL-283,ALA-286, GLY-281, HIS-61, HIS-263, HIS-85, and MET-280GLY-281, HIS-263, HIS-259, VAL-283, HIS-85, PHE-264, and VAL-248VAL-268, LEU-275, VAL-283, HIS-85, HIS-259, HIS-263, GLY-281, and ARG-268
Interaction typesπ–π stacked, hydrogen bonding, and π–alkylC-H bond, alkyl, π–π T-shaped, and alkyl–πCarbon–hydrogen bond, alkyl, π–alkyl, and π–donor hydrogen bond
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Kausar, R.; Zahoor, A.F.; Tabassum, H.; Kamal, S.; Ahmad Bhat, M. Synergistic Biomedical Potential and Molecular Docking Analyses of Coumarin–Triazole Hybrids as Tyrosinase Inhibitors: Design, Synthesis, In Vitro Profiling, and In Silico Studies. Pharmaceuticals 2024, 17, 532. https://doi.org/10.3390/ph17040532

AMA Style

Kausar R, Zahoor AF, Tabassum H, Kamal S, Ahmad Bhat M. Synergistic Biomedical Potential and Molecular Docking Analyses of Coumarin–Triazole Hybrids as Tyrosinase Inhibitors: Design, Synthesis, In Vitro Profiling, and In Silico Studies. Pharmaceuticals. 2024; 17(4):532. https://doi.org/10.3390/ph17040532

Chicago/Turabian Style

Kausar, Rukhsana, Ameer Fawad Zahoor, Hina Tabassum, Shagufta Kamal, and Mashooq Ahmad Bhat. 2024. "Synergistic Biomedical Potential and Molecular Docking Analyses of Coumarin–Triazole Hybrids as Tyrosinase Inhibitors: Design, Synthesis, In Vitro Profiling, and In Silico Studies" Pharmaceuticals 17, no. 4: 532. https://doi.org/10.3390/ph17040532

APA Style

Kausar, R., Zahoor, A. F., Tabassum, H., Kamal, S., & Ahmad Bhat, M. (2024). Synergistic Biomedical Potential and Molecular Docking Analyses of Coumarin–Triazole Hybrids as Tyrosinase Inhibitors: Design, Synthesis, In Vitro Profiling, and In Silico Studies. Pharmaceuticals, 17(4), 532. https://doi.org/10.3390/ph17040532

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop